Poly Medicure Ltd.POLYMED₹2,049.90 +3.37%

Poly Medicure Ltd., India’s leading medical device company, has announced the signing of a definitive agreement to acquire 100% stake in the Citieffe Group (Medistream SA and its subsidiaries in the USA & Mexico) for an Enterprise Value of ₹324 Crores (EUR 31 Million). This acquisition marks Polymed’s second major overseas acquisition within a month, strategically pivoting the company into the lucrative global orthopaedics segment.

Strategic Pivot into Orthopaedic Trauma

Citieffe, an Italy-based manufacturer founded in 1962, specializes in the development, manufacturing, and distribution of orthopaedic trauma and extremities fixation systems. This niche is particularly attractive as the trauma and extremities segment is described as the fastest-growing and most resilient category within the orthopaedics market, providing Polymed with a high-growth platform to build a global orthopaedic business.

The acquisition brings a robust and differentiated portfolio to Polymed:

  • Differentiated Portfolio: Citieffe’s product line includes a diverse, fully accredited, and patented portfolio of trauma and extremity products, backed by 45 patents and full regulatory clearances, including EU MDR and US FDA accreditation.
  • Global Footprint: Citieffe provides an immediate, direct sales presence in Italy, the USA, and Mexico, and distributes to over 25 countries. It holds a significant market position, being the #2 independent player in its targeted segment in Italy and one of the top players in Mexico, with a growing presence in the US, the world’s largest orthopaedic market.
  • Integrated Business: The Italian firm operates with an agile, integrated business model, controlling all processes from product R&D to manufacturing to sales.

In CY 2024, Citieffe reported healthy financials with EUR 17.3 million in revenue and EUR 3.1 million in EBITDA, reflecting strong year-on-year growth of 15% and 14% respectively. The transaction values the company at an EV/EBITDA multiple of 10.2x (FY 24 basis).

Synergies and Future Growth Plans

Polymed anticipates significant synergies by combining its massive manufacturing scale and global distribution network with Citieffe’s innovative R&D pipeline.

The move is “about creating long-term value” and allows them to “accelerate the expansion into orthopaedics adjacencies and expand reach to more patients globally.”

The expected synergies and growth plans include:

  • Cost Optimization: Outsourcing parts of Citieffe’s manufacturing process to Polymed’s state-of-the-art facilities in India to reduce the cost of the product, thereby boosting margins.
  • Market Expansion: Leveraging Polymed’s extensive network to introduce Citieffe’s products in India and expand its reach globally, while also bolstering the US business by hiring more sales representatives to capitalize on premium pricing in that market.
  • Product Line Expansion: Short-term plans include adding plates to the product portfolio, with a medium-term goal of entering the joints replacement market.

The acquisition is structured with an upfront payout of approximately EUR 23 million (including repayment of shareholder loan liabilities) and taking over net external debt. The existing management, including Mr. Pascal Govi, CEO, Citieffe, will continue to lead the company post-transaction, which is expected to close in the next 4–8 weeks.

Over the last three and five years, Polymed has delivered multibagger returns of more than 125% and 350%, respectively. 

Let’s take a look at its Factor Analysis scores:

Note: The stock price mentioned is as of 1:10 pm.

Disclaimer and Disclosure 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI, enlistment as Research Analyst with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Kindly refer to  https://share.market/ for more details.Investments in WealthBaskets are subject to the Terms of Service. All investors are advised to conduct their own independent research into investment strategies before making an investment decision. PPWB acts as a distributor of mutual funds and it is not an exchange traded product. PPWB acts as a distributor of mutual funds and WealthBaskets and it is not an exchange traded product. Disputes with respect to the distribution activity of Mutual Funds and WealthBaskets will not have access to Exchange investor redressal or Arbitration mechanism. The securities are quoted as an example and not as a recommendation. This is for informational purposes and should not be considered as recommendations.

PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887 and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226. Registered office – 2, Floor 3, Wing A, Block A, Salarpuria Softzone, Service Road, Green Glen Layout, Bellandur, Bengaluru South, Bengaluru, Karnataka – 560103, INDIA. CIN: U65990KA2021PTC146954